We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know
Read MoreHide Full Article
Ligand Pharmaceuticals (LGND - Free Report) closed at $58.75 in the latest trading session, marking a -0.71% move from the prior day. This change was narrower than the S&P 500's 1.37% loss on the day. Meanwhile, the Dow lost 1.29%, and the Nasdaq, a tech-heavy index, lost 1.87%.
Heading into today, shares of the drugmaker had lost 11.08% over the past month, lagging the Medical sector's loss of 4.07% and the S&P 500's loss of 4.93% in that time.
Wall Street will be looking for positivity from Ligand Pharmaceuticals as it approaches its next earnings report date. On that day, Ligand Pharmaceuticals is projected to report earnings of $0.68 per share, which would represent year-over-year growth of 65.85%. Meanwhile, our latest consensus estimate is calling for revenue of $27.11 million, down 58.98% from the prior-year quarter.
LGND's full-year Zacks Consensus Estimates are calling for earnings of $5.09 per share and revenue of $125 million. These results would represent year-over-year changes of +6.26% and -43.07%, respectively.
Investors should also note any recent changes to analyst estimates for Ligand Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 3.4% higher. Ligand Pharmaceuticals is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Ligand Pharmaceuticals is holding a Forward P/E ratio of 11.63. For comparison, its industry has an average Forward P/E of 17.04, which means Ligand Pharmaceuticals is trading at a discount to the group.
Also, we should mention that LGND has a PEG ratio of 0.58. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.06 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know
Ligand Pharmaceuticals (LGND - Free Report) closed at $58.75 in the latest trading session, marking a -0.71% move from the prior day. This change was narrower than the S&P 500's 1.37% loss on the day. Meanwhile, the Dow lost 1.29%, and the Nasdaq, a tech-heavy index, lost 1.87%.
Heading into today, shares of the drugmaker had lost 11.08% over the past month, lagging the Medical sector's loss of 4.07% and the S&P 500's loss of 4.93% in that time.
Wall Street will be looking for positivity from Ligand Pharmaceuticals as it approaches its next earnings report date. On that day, Ligand Pharmaceuticals is projected to report earnings of $0.68 per share, which would represent year-over-year growth of 65.85%. Meanwhile, our latest consensus estimate is calling for revenue of $27.11 million, down 58.98% from the prior-year quarter.
LGND's full-year Zacks Consensus Estimates are calling for earnings of $5.09 per share and revenue of $125 million. These results would represent year-over-year changes of +6.26% and -43.07%, respectively.
Investors should also note any recent changes to analyst estimates for Ligand Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 3.4% higher. Ligand Pharmaceuticals is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Ligand Pharmaceuticals is holding a Forward P/E ratio of 11.63. For comparison, its industry has an average Forward P/E of 17.04, which means Ligand Pharmaceuticals is trading at a discount to the group.
Also, we should mention that LGND has a PEG ratio of 0.58. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.06 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.